Sander, Cindy
Novartis (Switzerland) · Cleveland Clinic · The University of Texas MD Anderson Cancer Center · University of Pittsburgh · Bristol-Myers Squibb (United States) · Incyte (United States)
6 papers on CoChatORCID 0000-0002-4136-1342
Most cited papers
- Verified
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell
Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
Cited by 3,151
- Verified
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 1,307
- Verified
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell
T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers
Cited by 627
- Verified
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 394
- Verified
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 372
- Verified
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 86
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free